Abstract: The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.

Abstract: The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.

Abstract: The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.

Abstract: A sports gear carrying assembly includes a front plate that is worn on a user's back. The front plate has a plurality of front plate apertures extending therethrough. A back plate is coupled to the front plate and winter sports gear is positioned on the back plate. The back plate has a plurality of back plate apertures extending therethrough. An extension unit is slidably positioned between each of the front and back plates and the extension unit is laterally extendable a selected distance away from the front and back plates for accommodating a variety of widths of winter sports gear. A plurality of belts is each extended through a selected pair of the front and back plate apertures for securing the winter sports gear on the back plate. Each of the belts is matable to themselves to form a closed loop. A harness is coupled to the front plate and the harness is worn over the user's shoulders thereby facilitating the winter sports gear to be carried on the user's back.

Abstract: A controlled release system includes a polymeric support, wherein the polymeric support is biodegradable; a polymeric matrix, wherein the polymeric matrix includes polyhydroalkanoate; and encapsulated gases or volatiles; and a controlled release system includes a polymeric support; a polymeric matrix, wherein the polymeric matrix includes (poly-3-hydroxybutyrate-co-3-hydroxyvalerate) and poly (?-caprolactone); and encapsulated gases or volatiles.

Abstract: A controlled release system includes a polymeric support, wherein the polymeric support is biodegradable; a polymeric matrix, wherein the polymeric matrix includes polyhydroalkanoate; and encapsulated gases or volatiles; and a controlled release system includes a polymeric support; a polymeric matrix, wherein the polymeric matrix includes (poly-3-hydroxybutyrate-co-3-hydroxyvalerate) and poly (?-caprolactone); and encapsulated gases or volatiles.

Abstract: The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention.

Abstract: The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention.